Objective-Absence of stearoyl-CoA desaturase-1 (SCD1) in mice reduces plasma triglycerides and provides protection from obesity and insulin resistance, which would be predicted to be associated with reduced susceptibility to atherosclerosis. The aim of this study was to determine the effect of SCD1 deficiency on atherosclerosis. Methods and Results-Despite an antiatherogenic metabolic profile, SCD1 deficiency increases atherosclerosis in hyperlipidemic low-density lipoprotein receptor (LDLR)-deficient mice challenged with a Western diet. Lesion area at the aortic root is significantly increased in males and females in 2 models of SCD1 deficiency. Inflammatory changes are evident in the skin of these mice, including increased intercellular adhesion molecule (ICAM)-1 and ulcerative dermatitis. Increases in ICAM-1 and interleukin-6 are also evident in plasma of SCD1-deficient mice. HDL particles demonstrate changes associated with inflammation, including decreased plasma apoA-II and apoA-I and paraoxonase-1 and increased plasma serum amyloid A. Lipopolysaccharide-induced inflammatory response and cholesterol efflux are not altered in SCD1-deficient macrophages. In addition, when SCD1 deficiency is limited to bone marrow-derived cells, lesion size is not altered in LDLR-deficient mice. Key Words: atherosclerosis Ⅲ inflammation Ⅲ apolipoproteins Ⅲ lipoproteins Ⅲ hyperlipoproteinemia S tearoyl-CoA desaturase (SCD) is the rate-limiting enzyme in the synthesis of monounsaturated fatty acids. It creates a cis-double bond in the ⌬-9 position of palmitic (16:0) and stearic acid (18:0), thereby converting them to palmitoleic (16:1n7) and oleic acid (18:1n9). 1 Oleic acid is the major fatty acid found in triglycerides (TG) and cholesteryl esters (CE), 2 likely because of its status as the preferred fatty acid substrate of acyl-CoA:cholesterol acyltransferase (ACAT), 3 and the close proximity of SCD to diacylglycerol acyltransferase-2 in the endoplasmic reticulum (ER). 4 SCD1-deficient mice are protected from insulin resistance and diet-induced obesity 5 and have a markedly reduced rate of VLDL-TG production. 6 We have recently shown 7 that SCD1 deficiency improves the metabolic phenotype of a hyperlipidemic LDLR-deficient mouse model of familial hypercholesterolemia (FH). 8 On a Western diet, LDLRdeficient mice develop diet-induced diabetes and obesity and develop atherosclerosis over 2 to 3 months. 8 In the absence of the Scd1 gene product LDLR-deficient mice have reduced hepatic steatosis (by Ϸ80%) and plasma TG (by Ϸ50%). 7 Absence of SCD1 also provides striking protection from diet-induced weight gain and insulin resistance. A major unanswered question is whether the amelioration of these features of the metabolic syndrome in SCD1-deficient mice will lead to reduced susceptibility to atherosclerosis. In this study, we show that despite these antiatherogenic metabolic characteristics, SCD1 deficiency surprisingly increases lesion size in hyperlipidemic LDLRdeficient mice and that this acceleration in atherosclerosis is likely to result from chronic inflammation primarily of the skin, which then leads to changes in markers of inflammation in plasma and proinflammatory changes in HDL. mice that were not littermates (Ϸ63% of all animals studied). Mice deficient in SCD1 with the Scd1ab-J allele were used in all experiments except those involving analysis of atherosclerotic lesions and (paraoxonase-1) PON1 activity, in which mice carrying a separately derived SCD1 deletion (the Scd1ab-2J allele) were also studied. Sections of the aortic root were stained as described in Singaraga et al. 12 
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Methods
An extended Methods section is available in the online supplemental materials (please see http://atvb.ahajournals.org). Mice carrying the Scd1ab-J 9 or Scd1ab-2J 10 null alleles were back-crossed to C57BL/6 for 5 generations to produce N5 incipient congenic mice and then crossed to the B6.129S7-Ldlrtm1Her mutant strain. 11 The Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ control groups consisted of both littermates of Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice and additional additional age-and sex-matched Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ mice that were not littermates (Ϸ63% of all animals studied). Mice deficient in SCD1 with the Scd1ab-J allele were used in all experiments except those involving analysis of atherosclerotic lesions and (paraoxonase-1) PON1 activity, in which mice carrying a separately derived SCD1 deletion (the Scd1ab-2J allele) were also studied. Sections of the aortic root were stained as described in Singaraga et al. 12 
Results

SCD1 Deficiency Increases Atherosclerosis in
Mice with a spontaneous deletion in Scd1 (B6.ABJ/LeScd1ab-J) were crossed with an existing dyslipidemic mouse model (B6.129S7-Ldlrtm1Her) 11 to generate mice with combined deficiencies of both LDLR (Ldlr Ϫ/Ϫ ) and SCD1 (Scd1 Ϫ/Ϫ ). After 12 weeks of an atherogenic Western diet, 13 weights for male and female Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ mice were 44% and 54% higher than initial values, respectively, whereas neither male nor female Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice showed a significant increase in body weight, as described elsewhere. 7 Total plasma TG was reduced by 44% and 51%, and non-HDL cholesterol was reduced by 8% and 27% in male and female Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice, respectively, relative to Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ controls. HDL cholesterol levels were unchanged by SCD1 deficiency. Absence of SCD1 also increased insulin sensitivity as measured by intraperitoneal glucose and insulin tolerance testing. 7 Atherosclerotic lesion size was evaluated in multiple sections of the aortic root in this same cohort of Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice (males, nϭ6; females, nϭ10) and Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ control mice (males, nϭ11; females, nϭ11; Figure 1a and 1c). Unexpectedly, both male and female SCD1-deficient mice have significantly increased lesion size relative to controls. Lesion area was increased by 74% in males (Pϭ0.0002) and by 41% in females (Pϭ0.0004). In view of these observations in mice with the Scd1ab-J allele, we wished to examine whether these findings could be replicated in another cohort of mice carrying a different spontaneous null allele of Scd1 (B6.D1-Scd1ab-2J). 10 These mice were crossed with the same LDLR-deficient model and housed at a different specific pathogen-free barrier animal facility. Again, lesion area at the aortic root was increased in SCD1-deficient mice (129% increase in males; PϽ0.0001; 70% increase in females; PϽ0.0001; Figure 1b and 1c), thus supporting our initial findings. The effect remained significant when all mice that were not littermates were excluded from the analysis (data not shown). Aortic root sections from the first cohort of mice were stained with Movat pentachrome and hematoxylin and eosin (H&E) for histological examination. Extracellular matrix thickening and acellular areas containing cholesterol crystals were apparent in the deeper portion of the lesions from Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ mice (Figure 2a , 2b, and 2c). These findings were increased in the more advanced lesions of the Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice, with many extracellular cholesterol clefts in the large necrotic core underlying foam cell-rich regions. Staining for smooth muscle actin was evident in the media and fibrous caps of advanced lesions of both Scd1
Ldlr
Ϫ/Ϫ and Scd1 (Figure 2d ). The increased lesion size in Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice fed the Western diet for 12 weeks was characterized by greater absolute areas of macrophage infiltration in these animals versus Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ controls. This macrophage infiltration was evident in both the large complex atheromatous lesions in the left coronary sinuses, as well as the smaller lesions of the right coronary and noncoronary sinuses. The majority of cells in early plaques were positive for monocyte/macrophage staining in both Scd1
Ϫ/Ϫ and Scd1
Semiquantitative morphological examination of sections stained with Movat pentachrome and H&E was used to assign lesion severity scores on a 0 to 5ϩ scale based on the following parameters: foam cell characteristics, cholesterol clefts, presence of necrotic core, degree and composition of fibrous cap, infiltration into the media, extracellular matrix deposition, calcification, and plaque cellular characteristics. When examined in a blinded fashion, the aortic roots of Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice earned significantly higher lesion severity scores than Scd1
Ϫ/Ϫ controls (Pϭ0.001; Figure 2f ). (Figure 3c ). Severe spontaneous ulcerative dermatitis ( Figure   3d and 3e) necessitated euthanasia of 14% to 16% of SCD1-deficient mice (Figure 3f ). Diffuse inflammatory infiltration that included mast cells (Figure 3e ), exudation of inflammatory cells and fibrin onto the surface of the skin, and proliferation of fibrous tissue and granulation in the dermis was evident (Figure 3d and 3e) . We also observed mild to moderate lymphadenopathy, particularly protruding cervical and brachial lymph nodes, in mice with severe dermatitis. No Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ mice developed any skin lesions by the end of the study.
SCD1 Deficiency Promotes Inflammation in
These findings prompted us to examine whether SCD1-deficient mice also have markers of systemic inflammation that may be contributing to atherosclerosis. Interleukin (IL)-6 is increased by 67% (Pϭ0.043; Figure 4a ), and soluble ICAM-1, an adhesion molecule that is elevated in serum of patients with the inflammatory skin disorders psoriasis 16 and atopic eczema 17 was also increased in Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice (Pϭ0.0035; Figure 4b ). Two additional proinflammatory cytokines known to be elevated in psoriatric skin lesions, IL-1␤ 18 and IL-12p70, 19 were detected in plasma from Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice but not Scd1 ϩ/ϩ Ldlr Ϫ/Ϫ controls (Figure 4c and 4d) .
Circulating levels of MCP-1 were decreased 2-fold in Scd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice (Pϭ0.017; Figure 4e ). White adipose tissue is the major source of MCP-1 in obese mice, 20 and the decreased levels of MCP-1 may be attributed to the significant decreased in white adipose tissue see in Scd1
mice. 7 The levels of RANTES (CCL5) were not significantly different between Scd1 ( Figure 4f ). We also examined whether SCD1-deficient mice have increased markers of systemic inflammation in the absence of a proinflammatory dietary stimulus by measuring inflammatory changes before the commencement of a Western diet (Figure 4g ). In the absence of inflammatory stimuli, several of these inflammatory indicators are below the limit of detection in both Scd1
mice. Weak trends toward increased inflammatory indicators were seen in Scd1
controls, but these increases were not significant.
SCD1 Deficiency Alters HDL-Associated Proteins in Ldlr ؊/؊ Mice
We hypothesized that the chronic inflammation in SCD1-deficient mice may be associated with alterations in HDLassociated proteins, despite normal levels of HDL-cholesterol. 7 Inflammation has been shown to have a proatherogenic effect on the composition of HDL particles, such that they become depleted in specific proteins, such as apoA-I, apoA-II, and PON1, while enriched in serum amyloid A (SAA). 21 Indeed, in SCD1-deficient mice, plasma SAA is dramatically increased (females, 52-fold increase, Pϭ0.0087; males, 2.9-fold increase, Pϭ0.0043; Figure 5b ), whereas plasma apoA-I (females, Ϸ37% reduction, Pϭ0.0017; males, Ϸ16% reduction, Pϭ0.44; Figure 5c ) and apoA-II are decreased (Ϸ40% reduction; females, Pϭ0.0007; males, Pϭ0.0003; Figure 5d ). The changes in plasma SAA and apoA-II were paralleled by significant changes in mRNA encoding these genes (Saa1, Pϭ0.017; Saa2, Pϭ0.017; Apoa2, Pϭ0.039 Figure 5a ). Furthermore, hepatic mRNA levels of Pon1, the gene that encodes PON1, an enzyme that contributes to the antioxidant properties of HDL, 22 are decreased by nearly 75% (PϽ0.001; Figure 5a ), whereas mRNA levels of Clu, the gene that encodes apoJ/clusterin, an acute phase HDL-associated protein, 23 are increased by more than 2-fold (Pϭ0.0001; Figure  5a ). No changes were observed in mRNA levels of Lcat (Figure 5a ). SCD1-deficient mice also had a significantly lower serum PON1 activity (Pϭ0.0028; Figure 5e ). These data indicate that SCD1 has a proatherogenic effect on HDL protein composition that may be attributed to chronic inflammation.
SCD1 Deficiency Does Not Alter Macrophage Function
The atherogenic effect of SCD1 deficiency could result from increased systemic inflammation or a direct effect of SCD1 deficiency on macrophage function. If the increased macrophage infiltration is attributable to a direct effect of SCD1 deficiency in macrophages, we would expect an increased inflammatory response in SCD1-deficient macrophages. We therefore evaluated the effect of SCD1 deficiency on the inflammatory response of thioglycollate-elicited peritoneal exudate cells from Scd1
mice (Figure 6a ). Inflammatory gene expression was induced by lipopolysaccharide (LPS), an agonist of toll-like receptor 4 signaling, and mRNA levels of several LPS-induced inflammatory proteins were assessed. No significant differences were observed in genes encoding IL-6, TNF-␣, IL-1␤, IL12p35, iNOS, IP-10, GARG-16, or COX2, suggesting that the increased atherosclerosis observed with SCD1 deficiency is not attributable to an altered macrophage inflammatory response.
Macrophage SCD1 Deficiency Does Not Alter Atherosclerosis in Ldlr
؊/؊ Mice Another way to examine whether the atherogenic effect of SCD1 deficiency results from a direct effect on SCD1 deficiency in macrophages is to evaluate the effect of SCD1 deficiency in bone marrow-derived cells on atherosclerosis in vivo. Bone marrow from Scd1 Ϫ/Ϫ and Scd1 ϩ/ϩ mice was transplanted into LDLR-deficient mice. At 6 weeks after bone marrow transplantation, the diet was switched from regular chow diet to Western diet. After 6 weeks on the Western diet, no skin lesions were observed in the transplanted mice, nor did SCD1 deficiency in bone marrow-derived cells have an effect on serum lipids (supplemental Table I ). Most importantly, no effect was observed between the 2 transplanted groups on atherosclerotic lesion size (0.207Ϯ0.018 mm 2 in Scd1 ϩ/ϩ 3Ldlr Ϫ/Ϫ mice versus 0.189Ϯ0.029 mm 2 in Scd1 Ϫ/Ϫ 3Ldlr Ϫ/Ϫ mice; Figure 6b and 6c), indicating that loss of macrophage SCD1 does not directly play a significant role in atherogenesis in these mice.
Overexpression of SCD1 has been reported to result in decreased cholesterol efflux in HEK293 and CHO cells. 24 We therefore evaluated the ability of bone marrow-derived macrophages from Scd1 Ϫ/Ϫ 3Ldlr Ϫ/Ϫ and Scd1 ϩ/ϩ 3Ldlr Ϫ/Ϫ mice to efflux cholesterol to apoA-1 and HDL acceptors. SCD1 deficiency had no effect on cholesterol efflux to HDL under our experimental conditions (Figure 6d ), further supporting the fact that SCD1 deficiency is not associated with altered macrophage function.
Discussion
Despite an antiatherogenic lipid and metabolic profile, absence of SCD1 promotes inflammation and atherosclerosis in a mouse model of FH on a Western diet. Absence of SCD1 also increases plasma IL-6, IL-1␤, IL-12p70, and sICAM-1 levels and has a proinflammatory effect on the components of HDL particles, increasing SAA and apoJ/clusterin and reducing apoA-I, apoA-II, and PON1. A specific deficiency of SCD1 in bone marrow-derived cells does not influence atherosclerotic lesion size. We have recently shown that SCD1-deficient mice have relatively reduced plasma triglycerides and are protected from obesity and insulin resistance, 7 phenotypic components of the metabolic syndrome that have been linked to increased susceptibility to atherosclerosis. 25, 26 These surprising data suggested that SCD1-deficient mice must have some proatherogenic stimulus that overcomes the antiatherogenic metabolic characteristics expected to reduce lipid accumulation in the aorta. Chronic inflammation has been reported in the skin of chow-fed SCD1-deficient mice, indicated by increased mRNA encoding ICAM-1 15 and increased infiltration of macrophages and mast cells but only rare lymphocytes or neutrophils in the dermis. 14 In addition, subcutanous cyclosporin A can inhibit ICAM-1 expression and reduce mast cell numbers in the skin, restoring the wild-type skin phenotype. 15 Histopathologic studies in these mice have demonstrated that the chronic inflammatory reaction is a foreign body response, with extreme sebaceous gland hypoplasia in SCD1-deficient animals resulting in hair fiber perforation of the follicle base and a foreign body response to fragments of hair fiber in the dermis. 10 Inflammation is recognized to play a major role in all stages of atherogenesis, 27 and plasma markers of systemic inflammation are predictive for cardiovascular events in humans. 28, 29 Indeed, standard preventive drug therapies such as aspirin and statins are known to have antiinflammatory properties and have been shown to be most beneficial in individuals with elevated inflammatory markers at baseline, even in those with relatively low serum cholesterol levels. 30 Moreover, chronic inflammatory diseases such as psoriasis, 31 rheumatoid arthritis, 32 periodontal disease, 33 and systemic lupus erythematosus (SLE) 34 are associated with in- 
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creased cardiovascular risk. The association between chronic inflammatory disease and cardiovascular disease is particularly pronounced for SLE, as women with SLE have an estimated 50-fold increased risk of myocardial infarction compared with age-and sexmatched controls. 35 In the LDLRdeficient mouse model, used by several groups to study the link between chronic inflammation and atherosclerosis, 36, 37 plasma markers of systemic inflammation increase in response to dietary cholesterol, and these markers are associated with increased lesion area independent of plasma lipoprotein levels. 38 Our observations of increased plasma IL-6, a marker of systemic inflammation that is associated with atherosclerosis, 28 sICAM-1, an adhesion molecule that is elevated in serum of patients with inflammatory skin disorders, 16, 17 and IL-1␤ and IL-12p70, proinflammatory cytokines known to be elevated in psoriatric lesional skin, 18, 19 suggest that chronic inflammation of the skin may be contributing to the proatherogenic profile of SCD-1 deficient mice by creating an environment of chronic systemic inflammation. During an inflammatory response, HDL particles are known to become depleted in apoA-I, apoA-II, and PON1 and enriched in SAA, a liver-derived protein increased by Western diets and correlated with lesion area in LDLR-deficient mice. 21, 38 Our results show that absence of SCD1 has a proatherogenic effect on HDL composition. However, further studies are needed to fully explore the effect of SCD1 deficiency on HDL particle size, protein and lipid composition, as well as the effect on the function of these HDL particles. While we have not ruled out the possibility that the increased systemic inflammation with SCD1 deficiency is a consequence of increased atherosclerosis rather than its cause, alterations in multiple indicators of inflammation are consistent with a proatherogenic role for inflammation in the absence of murine SCD1.
Chen et al 39 have recently reported that SCD1 downregulation exacerbates the inflammatory response to acute proinflammatory stimuli. Although these authors evaluated dextran-sulfate sodium-induced colitis in SCD1-null mice, they attribute the accelerated response to reduced SCD1-mediated hepatic oleic acid biogenesis. We consider it unlikely that a reduction in hepatic SCD1 activity explains all the atherogenic effects on inflammatory markers in the SCD1-null model, however, because the phenotype of this model includes pronounced chronic dermal inflammation, a well-established contributor to systemic inflammation and cardiovascular disease in humans. 31 Atherosclerotic lesion size and macrophage cholesterol efflux are not altered in LDLR-deficient mice transplanted with bone marrow from SCD1-deficient mice. These observations, in addition to the lack of altered LPS-induced inflammatory response in SCD1-deficient peritoneal macrophages, suggest that macrophage SCD1 does not play a significant role in atherogenesis in this model. However, it should be noted that these results are from early lesions only, and a longer term study is needed of SCD1 in macrophages of atherosclerotic lesions.
The SCD1-deficient mouse model affords a unique opportunity to compare and contrast directly the effects of an antiatherogenic metabolic profile with proinflammatory pathways.
In this instance, proinflammatory pathways overcome the favorable metabolic profile. However, significant unanswered questions remain regarding possible atherogenic effects of circulating lipoproteins or tissue lipids with increased saturated fatty acids (SFA) or decreased monounsaturated fatty acids (MUFA), as shown in SCD1-deficient mice. 2, 40 The relevance of these findings to the development of SCD inhibitors for treatment of the metabolic syndrome in humans is unclear. Observational studies in humans have shown an association between increased indices of SCD activity and components of the metabolic syndrome, [41] [42] [43] inflammatory markers, 44 and potentially coronary heart disease, 45 suggesting that the atherogenic inflammation observed in this mouse model of SCD1 deficiency may not extend to humans with reduced SCD1 activity. The findings in this study represent the effects of long-term complete SCD1 deficiency in all tissues in mice. Antisense oligonucleotides (ASOs) may also be expected to result in near complete deficiency of SCD1 expression in some extrahepatic tissues, 46 which could lead to atherogenic inflammation in rodent models similar to that observed here. By contrast, pharmaceutical compounds are generally not used at levels that would cause complete inhibition of the target enzyme through a 24-hour cycle, and would not be distributed throughout all tissues in the body.
While this manuscript was in review, two different studies reported on the relationship between atherosclerosis and SCD1 deficiency mediated by ASOs. Both groups treated mice with identical SCD1-targeted ASOs, but the experiments yielded different results: increased atherosclerosis in the Ldlr Ϫ/Ϫ Apob100/100 model 47 and reduced atherosclerosis in the chronic intermittent hypoxia (CIH) model. 48 One clue to the discrepancy could be model-specific effects on HDLcholesterol levels, as SCD1 deficiency is accompanied by a Ϸ50% reduction of HDL-cholesterol levels in the dyslipidemic Ldlr Ϫ/Ϫ Apob100/100 model, 47 a change in HDL expected to be associated with increased atherosclerosis. 49 However, ASO-mediated SCD1 deficiency in the CIH model is accompanied by an atheroprotective Ϸ20% increase in HDLcholesterol levels. 48 Our results indicate that in the absence of changes in HDL cholesterol levels, complete and chronic SCD1 deficiency is likely to exacerbate atherosclerosis.
These studies now provide strong support for the role of chronic inflammation in promoting atherosclerosis, even in the presence of antiatherogenic biochemical and metabolic characteristics. Adjacent sections were stained with hematoxylin and eosin or Movat pentachrome as described in Singaraga et al (2) . Movat pentachrome staining was used for visualization of proteoglycan-rich, extracellular matrix thickening of the intimae (sea-green colour) and necrotic cores (absence of purple/black nuclei).
Image analysis was performed with Image Pro Plus (Media Cybernetics, Silver Springs, MD) or ImageJ (version 1.41b; National Institutes of Health, Baltimore, MD).
Measurements were made at a magnification of 4× after calibration of the image analysis software using a micrometer image scanned at a magnification identical to that used for the aortic root tissue.
It was critical to manually evaluate lesion area from the luminal edge to the intimamedia border rather than using threshold-based quantification of oil red O staining of neutral lipids, as we observed inconsistent staining between two studies and within lesions that contain regions of extracellular matrix and unesterified cholesterol. Values reported represent the mean lesion area from 4 sections for each animal.
Semi-quantitative assessment of lesion severity and inflammatory cell infiltration was performed in a randomized and blinded fashion by a registered cardiovascular pathologist (BMM) using a 0 to 5+ scale. To assess reproducibility of this analysis, randomly selected slides were used to assess intra-observer variability on two separate occasions. Qualitative 
